Incyte (INCY) Short-term Investments (2010 - 2026)
Incyte posted quarterly Short-term Investments of $554.7 million for Q1 2026, up 18.8% year-on-year from $466.9 million in Q1 2025, and up 14.9% on a QoQ basis from $482.8 million in Q4 2025.
Incyte (INCY) has 17 years of Short-term Investments data on file, last reported at $554.7 million in Q1 2026.
- For the quarter ending Q1 2026, Short-term Investments rose 18.8% year-over-year to $554.7 million; the trailing twelve-month figure through Mar 2026 stood at $554.7 million (up 18.8% YoY), and the FY2025 full-year result was $482.8 million, up 2.66% from the prior year.
- Short-term Investments for Q1 2026 stood at $554.7 million, up from $482.8 million in the prior quarter.
- Across five years, Short-term Investments topped out at $554.7 million in Q1 2026 and bottomed at $3.3 million in Q3 2024.
- The 5-year median for Short-term Investments is $442.7 million (2023), against an average of $373.6 million.
- The widest annual swing landed in 2024, when Short-term Investments slumped 98.84%; it then soared 14098.98% in 2025.
- A 5-year view of Short-term Investments shows it stood at $287.5 million in 2022, then jumped by 53.95% to $442.7 million in 2023, then advanced by 6.23% to $470.3 million in 2024, then grew by 2.66% to $482.8 million in 2025, then climbed by 14.9% to $554.7 million in 2026.
- The last three Short-term Investments figures came in at $554.7 million (Q1 2026), $482.8 million (Q4 2025), and $474.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 554.71 Mn |
| Dec 31, 2025 | 482.79 Mn |
| Sep 30, 2025 | 474.81 Mn |
| Jun 30, 2025 | 466.77 Mn |
| Mar 31, 2025 | 466.94 Mn |
| Dec 31, 2024 | 470.26 Mn |
| Sep 30, 2024 | 3.34 Mn |
| Jun 30, 2024 | 462.21 Mn |
| Mar 31, 2024 | 504.48 Mn |
| Dec 31, 2023 | 442.67 Mn |
| Sep 30, 2023 | 289.22 Mn |
| Jun 30, 2023 | 292.24 Mn |
| Mar 31, 2023 | 291.66 Mn |
| Dec 31, 2022 | 287.54 Mn |
| Sep 30, 2022 | 286.50 Mn |
| Jun 30, 2022 | 287.04 Mn |
| Mar 31, 2022 | 287.40 Mn |
| Dec 31, 2021 | 290.75 Mn |
| Sep 30, 2021 | 285.05 Mn |
| Jun 30, 2021 | 283.39 Mn |
| Mar 31, 2021 | 292.43 Mn |
| Dec 31, 2020 | 288.37 Mn |
| Sep 30, 2020 | 237.03 Mn |
| Jun 30, 2020 | 262.76 Mn |
| Mar 31, 2020 | 259.35 Mn |
| Dec 31, 2019 | 284.87 Mn |
| Jun 30, 2019 | 279.63 Mn |
| Mar 31, 2019 | 281.32 Mn |
| Dec 31, 2018 | 274.34 Mn |
| Sep 30, 2018 | 263.13 Mn |
| Jun 30, 2018 | 269.87 Mn |
| Mar 31, 2018 | 276.63 Mn |
| Dec 31, 2017 | 270.14 Mn |
| Sep 30, 2017 | 153.34 Mn |
| Jun 30, 2017 | 156.85 Mn |
| Mar 31, 2017 | 150.13 Mn |
| Dec 31, 2016 | 156.20 Mn |
| Sep 30, 2016 | 17,000.00 |
| Jun 30, 2016 | 16,000.00 |
| Mar 31, 2016 | 153.05 Mn |
| Dec 31, 2015 | 186.34 Mn |
| Sep 30, 2015 | 517,000.00 |
| Jun 30, 2015 | 517,000.00 |
| Mar 31, 2015 | 500,000.00 |
| Dec 31, 2014 | 500,000.00 |
| Sep 30, 2014 | 500,000.00 |
| Jun 30, 2014 | 102.49 Mn |
| Mar 31, 2014 | 625,000.00 |
| Dec 31, 2013 | 500,000.00 |
| Sep 30, 2013 | 19.05 Mn |
| Jun 30, 2013 | 19.25 Mn |
| Mar 31, 2013 | 4.37 Mn |
| Dec 31, 2012 | 4.36 Mn |
| Sep 30, 2012 | 4.52 Mn |
| Jun 30, 2012 | 4.24 Mn |
| Mar 31, 2012 | 4.56 Mn |
| Dec 31, 2011 | 4.43 Mn |
| Sep 30, 2011 | 4.65 Mn |
| Jun 30, 2011 | 5.04 Mn |
| Mar 31, 2011 | 5.78 Mn |
| Dec 31, 2010 | 6.26 Mn |